A Phase 3 interventional study of Ixekizumab and Placebo in Axial Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 127 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-13.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one has the largest enrollment of the 31 interventional ones that give a count, is the only one that started in 2017, is one of 13 in phase 3, and was the 13th registered.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
Browse Axial Spondyloarthritis studies →7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
CARE ARTHRITIS LTD. · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 773 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 200 across the 31 interventional studies, 50 across the 3 observational. Of the 21 that completed or were terminated, 17 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 34 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07836374University of MichiganRENEW Intervention for Axial Spondyloarthritis | 2027-03 |
| NCT07133633Merck Sharp & Dohme LLCA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | 2027-03-29 |
| NCT07642622University of WashingtonPhysical Activity Through Health Technology in Axial Spondyloarthritis | 2027-04 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
Drug: Ixekizumab
Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
Drug: Ixekizumab
Participants received subcutaneous dose of placebo.
Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)
A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 64
Percentage of Participants Who do Not Experience a Flare
A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 64
Change From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)
The mSASSS is a four-point scoring system for lateral radiographs of the lumbar and cervical spine and has been shown to reliably track disease progression over time, where: 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge. By the scoring system of mSASSS of the spinal x-rays, a total of 24 sites were scored on the lateral cervical and lumbar spine: the anterior corners of the vertebrae from lower border of C2 to upper border T1 (inclusive), and from lower border of T12 to upper border of S1 (inclusive). Each corner was scored from 0 to 3, resulting in a range from 0 \[no change\] to 72 \[progression\].
Time frame: Baseline, 2 Years
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 64
Percentage of Participants Achieving an ASAS40 Response
ASAS40 is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 64
Percentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness +0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 64
Percentage of Participants With Inactive Disease on the ASDAS (<1.3 Units)
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
Time frame: Week 64
Change From Baseline in the Individual Components of the ASAS Criteria
Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
Time frame: Week 64
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
BASMI is a combined index comprising of the following 5 clinical measurements of spinal mobility in participants with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the participant's limitation of movement due to their AS. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Chest Expansion in Centimeters
Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While participants have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Occiput to Wall Distance
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints
The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Percentage of Participants With Anterior Uveitis or Uveitis Flares
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
Time frame: Week 64
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)
The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in SF-36 Mental Component Summary (MCS) Score
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in ASAS Health Index (ASAS HI)
The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the participant needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score
The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0- to 100-mm visual analog scale (VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA participant population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
Time frame: Baseline, Week 64
Percentage of Participants With No New Syndesmophyte Formation
Percentage of participants with no new syndesmophyte formation was measured using the average of 2 selected readers of 3 readers.
Time frame: Week 56
Percentage of Participants With Anti-Ixekizumab Antibodies
A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline, Week 64
* Lead-In (Period 1): 24 weeks (Week 0 to Week 24) * Extension Period including Double-Blind, Placebo-Controlled, Randomized Withdrawal-Retreatment (RWR) (Period 2): 40 weeks (Week 24 to Week 64) * Long-Term Extension Period (Period 3): 40 weeks (Week 64 to Week 104) * Post-Treatment Follow-Up (Period 4): at least 12 weeks and up to 24 weeks after the date of the participant's ETV or last regularly scheduled visit.
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 350 | 423 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 348 | 423 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 335 | 406 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 15 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Surgery programmed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 255 | 318 | 48 | 54 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 0 | 0 | 255 | 318 | 47 | 54 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 234 | 312 | 42 | 45 | 32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 21 | 6 | 6 | 9 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 13 | 5 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Experienced flare | 0 | 0 | 0 | 0 | 5 | 6 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 9 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 8 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 306 | 177 | 45 | 42 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 287 | 146 | 40 | 37 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 31 | 5 | 5 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 7 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Escalated to ixe80q2w | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 0 | 2 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 11 | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 11 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Escalated to ixe80q2w | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 | 5 | 4 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 73 | 5 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-Randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 223 | 453 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 198 | 411 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 25 | 42 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 20 | 37 |
| Withdrew: Covid 19 restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Missed follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| Percentage of participants | Combined IXE | Placebo |
|---|---|---|
| Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment) | 83.3 | 54.7 |
A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| Percentage of participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants Who do Not Experience a Flare | 83.3 | 83.3 | 54.7 |
The mSASSS is a four-point scoring system for lateral radiographs of the lumbar and cervical spine and has been shown to reliably track disease progression over time, where: 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge. By the scoring system of mSASSS of the spinal x-rays, a total of 24 sites were scored on the lateral cervical and lumbar spine: the anterior corners of the vertebrae from lower border of C2 to upper border T1 (inclusive), and from lower border of T12 to upper border of S1 (inclusive). Each corner was scored from 0 to 3, resulting in a range from 0 \[no change\] to 72 \[progression\].
| Units on a Scale | IXE80Q4W | IXE80Q2W | Combined IXE |
|---|---|---|---|
| Change From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) | 0.41 ± 2.102 | 0.23 ± 1.387 | 0.32 ± 1.779 |
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response | 81.3 | 81.5 | 50.9 |
ASAS40 is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| Percentage of Participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving an ASAS40 Response | 79.2 | 79.6 | 43.4 |
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness +0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| Percentage of participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units | 79.2 | 74.1 | 45.3 |
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.
| Percentage of participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants With Inactive Disease on the ASDAS (<1.3 Units) | 60.4 | 53.7 | 24.5 |
Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| Units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Patient Global | -5.1 ± 0.38 | -5.0 ± 0.36 | -3.0 ± 0.36 |
| Spinal Pain | -5.1 ± 0.39 | -4.8 ± 0.37 | -3.0 ± 0.36 |
| BASFI | -4.35 ± 0.316 | -4.19 ± 0.301 | -2.79 ± 0.301 |
| Inflammation | -5.20 ± 0.336 | -4.83 ± 0.319 | -3.03 ± 0.317 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
| Percentage of participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response | 81.3 | 75.9 | 45.3 |
High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| milligram per liter (mg/L) | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP) | -12.952 ± 1.4666 | -11.074 ± 1.3861 | -5.094 ± 1.3696 |
BASMI is a combined index comprising of the following 5 clinical measurements of spinal mobility in participants with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the participant's limitation of movement due to their AS. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| Units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) | -0.69 ± 0.080 | -0.73 ± 0.075 | -0.50 ± 0.073 |
Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While participants have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| centimeter (cm) | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Chest Expansion in Centimeters | 0.77 ± 0.256 | 0.53 ± 0.243 | 0.67 ± 0.236 |
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| cm | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Occiput to Wall Distance | -0.78 ± 0.260 | -0.66 ± 0.239 | -0.38 ± 0.235 |
The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| Units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) | -3.55 ± 0.352 | -3.62 ± 0.315 | -3.48 ± 0.302 |
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| Units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score | -3.23 ± 0.388 | -3.34 ± 0.338 | -2.71 ± 0.335 |
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| Units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints | -6.1 ± 0.76 | -5.3 ± 0.74 | -4.0 ± 0.85 |
The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| Units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints | -3.6 ± 0.67 | -3.9 ± 0.59 | -2.7 ± 0.73 |
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
| Percentage of Participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants With Anterior Uveitis or Uveitis Flares | 4.2 | 5.6 | 5.7 |
The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score | -4.2 ± 0.31 | -4.3 ± 0.29 | -3.5 ± 0.28 |
The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16) | -3.68 ± 0.362 | -3.28 ± 0.344 | -2.80 ± 0.342 |
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score | 13.2954 ± 1.1210 | 13.1030 ± 1.0457 | 10.6934 ± 1.0366 |
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in SF-36 Mental Component Summary (MCS) Score | 3.1766 ± 0.8968 | 4.6404 ± 0.8369 | 2.3396 ± 0.8314 |
The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the participant needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in ASAS Health Index (ASAS HI) | -4.64 ± 0.393 | -4.37 ± 0.368 | -3.64 ± 0.370 |
The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0- to 100-mm visual analog scale (VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score | 0.2877 ± 0.0252 | 0.2847 ± 0.0235 | 0.2459 ± 0.0237 |
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA participant population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores | -43.58 ± 3.329 | -40.10 ± 3.115 | -32.96 ± 3.099 |
The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.
| units on a scale | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ) | -4.0 ± 0.50 | -3.8 ± 0.47 | -3.6 ± 0.47 |
Percentage of participants with no new syndesmophyte formation was measured using the average of 2 selected readers of 3 readers.
| Percentage of participants | IXE80Q4W | IXE80Q2W |
|---|---|---|
| Percentage of Participants With No New Syndesmophyte Formation | 80.9 | 87.8 |
A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| Percentage of participants | IXE80Q4W | IXE80Q2W | Placebo |
|---|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 4.7 | 2.0 | 20.0 |
Collected over Baseline, up to 128 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IXE 80Q4W-Lead-in Period | 0/348 (0%) | 10/348 (2.9%) | 79/348 (22.7%) |
| IXE80Q2W-Lead-in Period | 0/423 (0%) | 12/423 (2.8%) | 108/423 (25.5%) |
| IXE80Q4W-Group A Extension Period | 2/255 (0.8%) | 12/255 (4.7%) | 62/255 (24.3%) |
| IXE80Q2W-Group A Extension Period | 0/318 (0%) | 11/318 (3.5%) | 82/318 (25.8%) |
| IXE80Q4W-Group B-Randomized Withdrawal Extension Period | 0/47 (0%) | 2/47 (4.3%) | 8/47 (17%) |
| IXE80Q2W-Group B-Randomized Withdrawal Extension Period | 0/54 (0%) | 2/54 (3.7%) | 17/54 (31.5%) |
| Placebo-Group B-Randomized Withdrawal Extension Period | 0/53 (0%) | 1/53 (1.9%) | 16/53 (30.2%) |
| IXE80Q2W/IXE80Q2W-Retreatment Extension Period | 0/6 (0%) | 1/6 (16.7%) | 0/6 (0%) |
| IXE80Q4W/IXE80Q4W-Retreatment Extension Period | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| PBO/IXE80Q2W-Retreatment Extension Period | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| PBO/IXE80Q4W-Retreatment Extension Period | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| IXE80Q2W-group A Long-term Extension Period | 0/306 (0%) | 15/306 (4.9%) | 52/306 (17%) |
| IXE80Q4W-group A Long-term Extension Period | 0/177 (0%) | 3/177 (1.7%) | 37/177 (20.9%) |
| IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | 0/45 (0%) | 1/45 (2.2%) | 8/45 (17.8%) |
| IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | 0/42 (0%) | 1/42 (2.4%) | 6/42 (14.3%) |
| PBO-Group B-Randomized Withdrawal Long-term Extension Period | 0/30 (0%) | 0/30 (0%) | 9/30 (30%) |
| IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| PBO/IXE80Q2W-Retreatment Long-term Extension Period | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| PBO/IXE80Q4W-Retreatment Long-term Extension Period | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| IXE80Q4W-Group A-Escalation Period | 0/77 (0%) | 1/77 (1.3%) | 6/77 (7.8%) |
| IXE80Q4W-Randomized Withdrawal Escalation Period | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| PBO-randomized Withdrawal Escalation Period | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| PBO-follow-up Period | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| IXE80Q4W-follow-up Period | 1/223 (0.4%) | 3/223 (1.3%) | 14/223 (6.3%) |
| IXE80Q2W-follow-up Period | 0/453 (0%) | 2/453 (0.4%) | 27/453 (6%) |
| Event | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InfluenzaInfections and infestations | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 0/54 | 0/53 | 1/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 0/130 | 0/68 | 0/95 | 1/10 | 0/14 | 0/15 | 0/2 | 0/1 | 0/2 | 0/2 | 0/91 | 0/47 | 0/11 | 0/9 | 0/9 | 0/2 | 0/1 | 0/3 | 0/3 | 0/21 | 0/2 | 0/3 | 0/8 | 0/57 | 0/136 |
| UreterolithiasisRenal and urinary disorders | 0/348 | 0/423 | 1/255 | 0/318 | 0/47 | 0/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 1/306 | 0/177 | 0/45 | 1/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Acute myocardial infarctionCardiac disorders | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 0/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 1/306 | 0/177 | 1/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Compression fractureInjury, poisoning and procedural complications | 0/348 | 0/423 | 0/255 | 0/318 | 1/47 | 0/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Soft tissue inflammationGeneral disorders | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 0/54 | 1/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Chronic tonsillitisInfections and infestations | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 1/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Clostridium difficile colitisInfections and infestations | 1/348 | 0/423 | 0/255 | 0/318 | 0/47 | 1/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| MyelopathyNervous system disorders | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 1/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Myocardial infarctionCardiac disorders | 0/348 | 0/423 | 1/255 | 0/318 | 0/47 | 0/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 1/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 1/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Event | IXE 80Q4W-Lead-in Period | IXE80Q2W-Lead-in Period | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Extension Period | PBO/IXE80Q2W-Retreatment Extension Period | PBO/IXE80Q4W-Retreatment Extension Period | IXE80Q2W-group A Long-term Extension Period | IXE80Q4W-group A Long-term Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period | PBO-Group B-Randomized Withdrawal Long-term Extension Period | IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period | IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period | PBO/IXE80Q2W-Retreatment Long-term Extension Period | PBO/IXE80Q4W-Retreatment Long-term Extension Period | IXE80Q4W-Group A-Escalation Period | IXE80Q4W-Randomized Withdrawal Escalation Period | PBO-randomized Withdrawal Escalation Period | PBO-follow-up Period | IXE80Q4W-follow-up Period | IXE80Q2W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 1/348 | 0/423 | 0/255 | 2/318 | 0/47 | 0/54 | 0/53 | 0/6 | 1/5 | 0/9 | 0/10 | 2/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 1/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 1/453 |
| ToothacheGastrointestinal disorders | 1/348 | 1/423 | 1/255 | 1/318 | 0/47 | 1/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 1/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 1/4 | 0/11 | 0/15 | 1/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Neutrophil count decreasedInvestigations | 0/348 | 1/423 | 0/255 | 0/318 | 1/47 | 0/54 | 0/53 | 0/6 | 1/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 1/42 | 0/30 | 0/6 | 1/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| EnthesopathyMusculoskeletal and connective tissue disorders | 3/348 | 3/423 | 1/255 | 0/318 | 1/47 | 1/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 1/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Covid-19Infections and infestations | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 0/54 | 0/53 | 0/6 | 0/5 | 0/9 | 0/10 | 3/306 | 0/177 | 0/45 | 0/42 | 1/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 1/5 | 0/4 | 0/25 | 0/223 | 3/453 |
| Gastrointestinal viral infectionInfections and infestations | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 0/54 | 0/53 | 0/6 | 1/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| NasopharyngitisInfections and infestations | 27/348 | 40/423 | 27/255 | 30/318 | 2/47 | 4/54 | 7/53 | 0/6 | 1/5 | 1/9 | 0/10 | 19/306 | 17/177 | 2/45 | 1/42 | 3/30 | 0/6 | 0/4 | 1/11 | 2/15 | 2/77 | 1/5 | 0/4 | 0/25 | 4/223 | 6/453 |
| Foreign body in eyeInjury, poisoning and procedural complications | 0/348 | 0/423 | 0/255 | 0/318 | 0/47 | 0/54 | 0/53 | 0/6 | 1/5 | 0/9 | 0/10 | 0/306 | 0/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 0/223 | 0/453 |
| Back painMusculoskeletal and connective tissue disorders | 9/348 | 15/423 | 3/255 | 3/318 | 1/47 | 3/54 | 2/53 | 0/6 | 1/5 | 1/9 | 0/10 | 2/306 | 1/177 | 0/45 | 0/42 | 0/30 | 0/6 | 0/4 | 0/11 | 0/15 | 0/77 | 0/5 | 0/4 | 0/25 | 2/223 | 2/453 |
| Upper respiratory tract infectionInfections and infestations | 16/348 | 22/423 | 7/255 | 13/318 | 2/47 | 4/54 | 2/53 | 0/6 | 0/5 | 1/9 | 0/10 | 8/306 | 3/177 | 2/45 | 1/42 | 2/30 | 0/6 | 0/4 | 0/11 | 0/15 | 2/77 | 0/5 | 0/4 | 0/25 | 2/223 | 1/453 |
All randomized participants from extension period (period 2).
| Age, Categorical(Participants) | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 240 | 302 | 48 | 53 | 52 | 695 |
| >=65 years | 15 | 16 | 0 | 1 | 1 | 33 |
| Sex: Female, Male(Participants) | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | Total |
|---|---|---|---|---|---|---|
| Female | 68 | 95 | 10 | 14 | 15 | 202 |
| Male | 187 | 223 | 38 | 40 | 38 | 526 |
| Ethnicity (NIH/OMB)(Participants) | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 61 | 86 | 7 | 14 | 11 | 179 |
| Not Hispanic or Latino | 166 | 204 | 31 | 35 | 39 | 475 |
| Unknown or Not Reported | 28 | 28 | 10 | 5 | 3 | 74 |
| Race (NIH/OMB)(Participants) | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 14 | 11 | 2 | 5 | 4 | 36 |
| Asian | 54 | 50 | 15 | 15 | 13 | 147 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 0 | 0 | 2 |
| White | 183 | 247 | 31 | 31 | 35 | 527 |
| More than one race | 3 | 8 | 0 | 3 | 1 | 15 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | IXE80Q4W-Group A Extension Period | IXE80Q2W-Group A Extension Period | IXE80Q4W-Group B-Randomized Withdrawal Extension Period | IXE80Q2W-Group B-Randomized Withdrawal Extension Period | Placebo-Group B-Randomized Withdrawal Extension Period | Total |
|---|---|---|---|---|---|---|
| Argentina | 11 | 18 | 1 | 1 | 2 | 33 |
| Romania | 1 | 3 | 0 | 1 | 0 | 5 |
| Hungary | 3 | 2 | 1 | 1 | 0 | 7 |
| United States | 14 | 30 | 1 | 3 | 2 | 50 |
| Czechia | 37 | 35 | 5 | 4 | 4 | 85 |
| Japan | 7 | 9 | 1 | 3 | 1 | 21 |
| United Kingdom | 4 | 6 | 0 | 1 | 0 | 11 |
| Spain | 5 | 4 | 0 | 1 | 0 | 10 |
| Russia | 16 | 30 | 6 | 7 | 6 | 65 |
| Canada | 3 | 2 | 1 | 0 | 2 | 8 |
| Netherlands | 0 | 2 | 0 | 0 | 0 | 2 |
| South Korea | 28 | 23 | 10 | 7 | 8 | 76 |
| Austria | 1 | 1 | 0 | 1 | 0 | 3 |
| Taiwan | 17 | 16 | 3 | 5 | 2 | 43 |
| Finland | 0 | 5 | 0 | 1 | 2 | 8 |
| Brazil | 7 | 16 | 0 | 0 | 0 | 23 |
| Poland | 50 | 67 | 13 | 7 | 13 | 150 |
| Italy | 0 | 1 | 0 | 0 | 0 | 1 |
| Mexico | 40 | 38 | 5 | 11 | 8 | 102 |
| Israel | 5 | 3 | 0 | 0 | 1 | 9 |
| France | 4 | 4 | 0 | 0 | 0 | 8 |
| Germany | 2 | 3 | 1 | 0 | 2 | 8 |
Showing the first 100 of 127 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2017 to primary completion in May 2020, 36 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab